{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T06:13:39Z","timestamp":1792476819097,"version":"4.5.0"},"reference-count":94,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT-159807"],"award-info":[{"award-number":["PJT-159807"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000143","name":"Alzheimer Society of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000143","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012498","name":"Alzheimer Society Research Program","doi-asserted-by":"publisher","award":["0000000081"],"award-info":[{"award-number":["0000000081"]}],"id":[{"id":"10.13039\/100012498","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.pnpbp.2025.111541","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T06:45:37Z","timestamp":1761201937000},"page":"111541","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Adverse event reporting and management in psilocybin therapy clinical trials: A systematic review to guide clinical and research protocol development"],"prefix":"10.1016","volume":"143","author":[{"given":"Danielle","family":"Bukovsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aron","family":"Amaev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianmeng","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannen","family":"Kyte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgardo","family":"Carmona-Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihiko","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Deluca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio P.","family":"Strafella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad I.","family":"Husain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Graff-Guerrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Gerretsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pnpbp.2025.111541_bb0010","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1001\/jamapsychiatry.2023.4685","article-title":"Single-dose synthetic psilocybin with psychotherapy for treatment-resistant bipolar type II major depressive episodes: a nonrandomized open-label trial","volume":"81","author":"Aaronson","year":"2024","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.pnpbp.2025.111541_bb0015","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1007\/s00213-022-06123-7","article-title":"Great expectations: recommendations for improving the methodological rigor of psychedelic clinical trials","volume":"239","author":"Aday","year":"2022","journal-title":"Psychopharmacology (Berl)"},{"issue":"1","key":"10.1016\/j.pnpbp.2025.111541_bib487","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1037\/adb0000935","article-title":"Reports of self-compassion and affect regulation in psilocybin-assisted therapy for alcohol use disorder: An interpretive phenomenological analysis","volume":"38","author":"Agin-Liebes","year":"2024","journal-title":"Psychol. addict. behav.: J. Soc. Psychol. Addict. Behav."},{"key":"10.1016\/j.pnpbp.2025.111541_bb0020","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/cncr.35010","article-title":"Psilocybin-assisted group therapy in patients with cancer diagnosed with a major depressive disorder","volume":"130","author":"Agrawal","year":"2024","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.pnpbp.2025.111541_bib486","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2174\/1874473708666150107120930","article-title":"A qualitative report on the subjective experience of intravenous psilocybin administered in an FMRI environment","volume":"7","author":"Turton","year":"2014","journal-title":"Curr. Drug Abuse Rev."},{"key":"10.1016\/j.pnpbp.2025.111541_bb0110","series-title":"FDA issues first draft guidance on clinical trials with psychedelic drugs","author":"U.S. Food and Drug Administration (FDA)","year":"2024"},{"key":"10.1016\/j.pnpbp.2025.111541_bb0025","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1080\/14740338.2022.2047929","article-title":"The therapeutic potential of psilocybin: a systematic review","volume":"21","author":"van Amsterdam","year":"2022","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.pnpbp.2025.111541_bb0030","first-page":"27","article-title":"Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: an open-label safety and feasibility pilot study","author":"Anderson","year":"2020","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.pnpbp.2025.111541_bb0035","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1177\/0269881116678781","article-title":"The challenging experience questionnaire: characterization of challenging experiences with psilocybin mushrooms","volume":"30","author":"Barrett","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2025.111541_bb0040","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/cpt.2487","article-title":"Acute effects of psilocybin after escitalopram or placebo Pretreatment in a randomized, double-blind, placebo-controlled, crossover study in healthy subjects","volume":"111","author":"Becker","year":"2022","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.pnpbp.2025.111541_bb0045","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/0269881114565144","article-title":"Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study","volume":"29","author":"Bogenschutz","year":"2015","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2025.111541_bb0050","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jamapsychiatry.2022.2096","article-title":"Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial","volume":"79","author":"Bogenschutz","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.pnpbp.2025.111541_bb0055","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s00213-017-4807-2","article-title":"Psilocybin disrupts sensory and higher order cognitive processing but not pre-attentive cognitive processing-study on P300 and mismatch negativity in healthy volunteers","volume":"235","author":"Bravermanova","year":"2018","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.pnpbp.2025.111541_bb0060","series-title":"BREAKING: FDA Publishes Lykos Therapeutics\u2019 MDMA Complete Response Letter (CRL)","article-title":"Psychedelic Alpha","year":"2025"},{"key":"10.1016\/j.pnpbp.2025.111541_bb0065","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1177\/02698811221116926","article-title":"Adverse events in clinical treatments with serotonergic psychedelics and MDMA: a mixed-methods systematic review","volume":"36","author":"Breeksema","year":"2022","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2025.111541_bb0070","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1007\/s40262-017-0540-6","article-title":"Pharmacokinetics of escalating doses of Oral psilocybin in healthy adults","volume":"56","author":"Brown","year":"2017","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.pnpbp.2025.111541_bb0075","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jad.2024.08.091","article-title":"Validation of the Swiss psychedelic side effects inventory: standardized assessment of adverse effects in studies of psychedelics and MDMA","volume":"365","author":"Calder","year":"2024","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.pnpbp.2025.111541_bb0080","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1177\/0269881116662634","article-title":"Survey study of challenging experiences after ingesting psilocybin mushrooms: acute and enduring positive and negative consequences","volume":"30","author":"Carbonaro","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2025.111541_bb0085","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s00213-017-4769-4","article-title":"Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: similarities and differences in subjective experiences","volume":"235","author":"Carbonaro","year":"2018","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pnpbp.2025.111541_bb0090","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","article-title":"Trial of psilocybin versus escitalopram for depression","volume":"384","author":"Carhart-Harris","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pnpbp.2025.111541_bb0095","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1177\/0269881110367445","article-title":"The administration of psilocybin to healthy, hallucinogen-experienced volunteers in a mock-functional magnetic resonance imaging environment: a preliminary investigation of tolerability","volume":"25","author":"Carhart-Harris","year":"2011","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2025.111541_bb0100","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","article-title":"Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study","volume":"3","author":"Carhart-Harris","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.pnpbp.2025.111541_bb0105","author":"Center for Psychedelic & Consciousness Research"},{"key":"10.1016\/j.pnpbp.2025.111541_bb0120","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/cpdd.796","article-title":"Exposure-response analysis to assess the concentration-QTc relationship of psilocybin\/psilocin","volume":"10","author":"Dahmane","year":"2021","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.pnpbp.2025.111541_bb0125","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","article-title":"Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial","volume":"78","author":"Davis","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.pnpbp.2025.111541_bb0130","series-title":"Psychiatry Online. DSM Library","author":"Diagnostic and Statistical Manual of Mental Disorders","year":"2025"},{"key":"10.1016\/j.pnpbp.2025.111541_bb0135","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1176\/appi.ajp.20230572","article-title":"Psilocybin without psychotherapy: a cart without a horse?","volume":"181","author":"Earleywine","year":"2024","journal-title":"AJP"},{"key":"10.1016\/j.pnpbp.2025.111541_bb0140","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.eurpsy.2005.04.008","article-title":"Hallucinogen persisting perception disorder after psilocybin consumption: a case study","volume":"20","author":"Espiard","year":"2005","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.pnpbp.2025.111541_bb0145","doi-asserted-by":"crossref","first-page":"4062","DOI":"10.1021\/acschemneuro.3c00692","article-title":"Expectancy effects cannot be neglected in MDMA-assisted therapy research","volume":"14","author":"Flameling","year":"2023","journal-title":"ACS Chem. Nerosci."},{"key":"10.1016\/j.pnpbp.2025.111541_bb0150","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1177\/00048674241289024","article-title":"The safety of psilocybin-assisted psychotherapy: a systematic review","volume":"59","author":"Freitas","year":"2025","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2025.111541_bb0155","article-title":"Potential therapeutic effects of psilocybin: a systematic review","volume":"14","author":"Goel","year":"2025","journal-title":"Cureus"},{"key":"10.1016\/j.pnpbp.2025.111541_bb0160","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","article-title":"Single-dose psilocybin for a treatment-resistant episode of major depression","volume":"387","author":"Goodwin","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pnpbp.2025.111541_bb0165","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jad.2023.01.108","article-title":"Single-dose psilocybin for a treatment-resistant episode of major depression: impact on patient-reported depression severity, anxiety, function, and quality of life","volume":"327","author":"Goodwin","year":"2023","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.pnpbp.2025.111541_bb0170","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s00213-006-0457-5","article-title":"Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance","volume":"187","author":"Griffiths","year":"2006","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pnpbp.2025.111541_bb0175","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1177\/0269881108094300","article-title":"Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later","volume":"22","author":"Griffiths","year":"2008","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2025.111541_bb0180","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s00213-011-2358-5","article-title":"Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects","volume":"218","author":"Griffiths","year":"2011","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.pnpbp.2025.111541_bb0185","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial","volume":"30","author":"Griffiths","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2025.111541_bb0190","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/0269881117731279","article-title":"Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors","volume":"32","author":"Griffiths","year":"2018","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2025.111541_bb0195","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/archgenpsychiatry.2010.116","article-title":"Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer","volume":"68","author":"Grob","year":"2011","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.pnpbp.2025.111541_bb0200","series-title":"The Yale Manual for Psilocybin-Assisted Therapy of Depression (using Acceptance and Commitment Therapy as a Therapeutic Frame)","author":"Guss","year":"2020"},{"key":"10.1016\/j.pnpbp.2025.111541_bb0205","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0376-8716(02)00306-X","article-title":"Hallucinogen persisting perception disorder: what do we know after 50 years?","volume":"69","author":"Halpern","year":"2003","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.pnpbp.2025.111541_bb0210","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0731-7085(02)00278-9","article-title":"Renal excretion profiles of psilocin following oral administration of psilocybin: a controlled study in man","volume":"30","author":"Hasler","year":"2002","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.pnpbp.2025.111541_bb0215","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s00213-003-1640-6","article-title":"Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose\u2013effect study","volume":"172","author":"Hasler","year":"2004","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pnpbp.2025.111541_bb0220","article-title":"Nature-themed video intervention may improve cardiovascular safety of psilocybin-assisted therapy for alcohol use disorder","volume":"14","author":"Heinzerling","year":"2023","journal-title":"Front. Psych."},{"key":"10.1016\/j.pnpbp.2025.111541_bb0225","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1001\/jamapsychiatry.2024.2546","article-title":"Adverse events in studies of classic psychedelics: a systematic review and Meta-analysis","volume":"81","author":"Hinkle","year":"2024","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.pnpbp.2025.111541_bb0230","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/s41386-022-01297-2","article-title":"Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects","volume":"47","author":"Holze","year":"2022","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2025.111541_bb0235","doi-asserted-by":"crossref","DOI":"10.1192\/bjo.2023.535","article-title":"Psilocybin for treatment-resistant depression without psychedelic effects: study protocol for a 4-week, double-blind, proof-of-concept randomised controlled trial","volume":"9","author":"Husain","year":"2023","journal-title":"BJPsych Open"},{"key":"10.1016\/j.pnpbp.2025.111541_bb0240","article-title":"Psilocybin as a treatment for psychiatric illness: a Meta-analysis","volume":"14","author":"Irizarry","year":"2025","journal-title":"Cureus"},{"key":"10.1016\/j.pnpbp.2025.111541_bb0245","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1177\/0269881108093587","article-title":"Human hallucinogen research: guidelines for safety","volume":"22","author":"Johnson","year":"2008","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2025.111541_bb0250","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1177\/0269881114548296","article-title":"Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction","volume":"28","author":"Johnson","year":"2014","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2025.111541_bb0255","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jpainsymman.2023.06.006","article-title":"HOPE: a pilot study of psilocybin enhanced group psychotherapy in patients with Cancer","volume":"66","author":"Lewis","year":"2023","journal-title":"J. Pain Symptom Manage."},{"key":"10.1016\/j.pnpbp.2025.111541_bb0260","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1038\/s41386-023-01607-2","article-title":"Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants","volume":"48","author":"Ley","year":"2023","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2025.111541_bb0265","article-title":"Footage of therapists spooning and pinning down patient in B.C. trial for MDMA therapy prompts review","author":"Lindsay","year":"2022","journal-title":"CBC News"},{"key":"10.1016\/j.pnpbp.2025.111541_bb0270","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0447.1987.tb10566.x","article-title":"The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients","volume":"334","author":"Lingjaerde","year":"1987","journal-title":"Acta Psychiatr. Scand. Suppl."},{"key":"10.1016\/j.pnpbp.2025.111541_bb0275","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1016\/j.celrep.2018.05.022","article-title":"Psychedelics promote structural and functional neural plasticity","volume":"23","author":"Ly","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.pnpbp.2025.111541_bb0285","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/head.14656","article-title":"CCH attack frequency reduction after psilocybin correlates with hypothalamic functional connectivity","volume":"64","author":"Madsen","year":"2024","journal-title":"Headache"},{"key":"10.1016\/j.pnpbp.2025.111541_bb0290","article-title":"Updated cost-effectiveness of MDMA-assisted therapy for the treatment of posttraumatic stress disorder in the United States: findings from a phase 3 trial","volume":"17","author":"Marseille","year":"2022","journal-title":"PloS One"},{"key":"10.1016\/j.pnpbp.2025.111541_bb0295","article-title":"Group psychedelic therapy: empirical estimates of cost-savings and improved access","volume":"14","author":"Marseille","year":"2023","journal-title":"Front. Psych."},{"key":"10.1016\/j.pnpbp.2025.111541_bb0300","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): an R package and shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness","year":"2021","journal-title":"Res. Synth. Methods"},{"key":"10.1016\/j.pnpbp.2025.111541_bb0305","article-title":"Therapeutic effect of psilocybin in addiction: a systematic review","volume":"14","author":"van der Meer","year":"2023","journal-title":"Front. Psych."},{"key":"10.1016\/j.pnpbp.2025.111541_bb0310","doi-asserted-by":"crossref","first-page":"18864","DOI":"10.4088\/JCP.v67n1110","article-title":"Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder","volume":"67","author":"Moreno","year":"2006","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.pnpbp.2025.111541_bb0315","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1080\/17512433.2021.1933434","article-title":"Blinding and expectancy confounds in psychedelic randomized controlled trials","volume":"14","author":"Muthukumaraswamy","year":"2021","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"10.1016\/j.pnpbp.2025.111541_bb0325","doi-asserted-by":"crossref","first-page":"139","DOI":"10.31887\/DCNS.2019.21.2\/dnutt","article-title":"Psychedelic drugs\u2014a new era in psychiatry?","volume":"21","author":"Nutt","year":"2019","journal-title":"Dialogues Clin. Neurosci."},{"key":"10.1016\/j.pnpbp.2025.111541_bb0330","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.cell.2020.03.020","article-title":"Psychedelic psychiatry\u2019s brave New World","volume":"181","author":"Nutt","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.pnpbp.2025.111541_bb0335","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.pnpbp.2025.111541_bb0340","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1038\/s41591-023-02455-9","article-title":"Psilocybin therapy for females with anorexia nervosa: a phase 1, open-label feasibility study","volume":"29","author":"Peck","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.pnpbp.2025.111541_bb0345","series-title":"Encyclopedia of Toxicology","first-page":"418","article-title":"Mushroom, psilocybin","author":"Peredy","year":"2014"},{"key":"10.1016\/j.pnpbp.2025.111541_bb0350","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.euroneuro.2023.07.011","article-title":"Psilocybin-assisted therapy for depression: a systematic review and dose-response meta-analysis of human studies","volume":"76","author":"Perez","year":"2023","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.pnpbp.2025.111541_bb0355","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","article-title":"The Columbia-suicide severity rating scale: initial validity and inter nal consistency findings from three multisite studies with adolescents and adults","volume":"168","author":"Posner","year":"2011","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2025.111541_bb0360","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/jama.2023.14530","article-title":"Single-dose psilocybin treatment for major depressive disorder: a randomized clinical trial","volume":"330","author":"Raison","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.pnpbp.2025.111541_bb0365","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2024.115880","article-title":"Safety and risk assessment of psychedelic psychotherapy: a meta-analysis and systematic review","volume":"335","author":"Romeo","year":"2024","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.pnpbp.2025.111541_bb0370","doi-asserted-by":"crossref","first-page":"974","DOI":"10.3389\/fphar.2017.00974","article-title":"Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression","volume":"8","author":"Roseman","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.pnpbp.2025.111541_bb0375","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2024.01.005","article-title":"Psilocybin-assisted psychotherapy for treatment resistant depression: a randomized clinical trial evaluating repeated doses of psilocybin","author":"Rosenblat","year":"2024","journal-title":"Medicine"},{"key":"10.1016\/j.pnpbp.2025.111541_bb0380","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1177\/0269881116675512","article-title":"Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial","volume":"30","author":"Ross","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2025.111541_bb0385","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1080\/14740338.2022.2066650","article-title":"Safety issues of psilocybin and LSD as potential rapid acting antidepressants and potential challenges","volume":"21","author":"Rossi","year":"2022","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.pnpbp.2025.111541_bb0390","article-title":"Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial","volume":"56","author":"von Rotz","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.pnpbp.2025.111541_bb0395","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1177\/02698811211064720","article-title":"The effects of psilocybin on cognitive and emotional functions in healthy participants: results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration and preparation","volume":"36","author":"Rucker","year":"2022","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2025.111541_bb0400","doi-asserted-by":"crossref","first-page":"829","DOI":"10.3390\/brainsci14080829","article-title":"Comparison between single-dose and two-dose psilocybin Administration in the Treatment of major depression: a systematic review and Meta-analysis of current clinical trials","volume":"14","author":"Salvetti","year":"2024","journal-title":"Brain Sci."},{"key":"10.1016\/j.pnpbp.2025.111541_bb0405","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1007\/s13311-020-00962-y","article-title":"Exploratory controlled study of the migraine-suppressing effects of psilocybin","volume":"18","author":"Schindler","year":"2021","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.pnpbp.2025.111541_bb0410","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1111\/head.14420","article-title":"Exploratory investigation of a patient-informed low-dose psilocybin pulse regimen in the suppression of cluster headache: results from a randomized, double-blind, placebo-controlled trial","volume":"62","author":"Schindler","year":"2022","journal-title":"Headache"},{"key":"10.1016\/j.pnpbp.2025.111541_bb0415","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jpsychires.2023.03.031","article-title":"Pilot study of single-dose psilocybin for serotonin reuptake inhibitor-resistant body dysmorphic disorder","volume":"161","author":"Schneier","year":"2023","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.pnpbp.2025.111541_bb0420","doi-asserted-by":"crossref","first-page":"S635","DOI":"10.1016\/j.jval.2024.10.3190","article-title":"SA109 quality assessment tools for single-arm studies: a rapid review","volume":"27","author":"Shapiro","year":"2024","journal-title":"Value Health"},{"key":"10.1016\/j.pnpbp.2025.111541_bb0425","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.jad.2022.11.046","article-title":"Psilocybin-assisted therapy improves psycho-social-spiritual well-being in cancer patients","volume":"323","author":"Shnayder","year":"2023","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.pnpbp.2025.111541_bb0430","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1177\/02698811231154852","article-title":"Psilocybin-assisted therapy for major depressive disorder: an exploratory placebo-controlled, fixed-order trial","volume":"37","author":"Sloshower","year":"2023","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2025.111541_bb0440","doi-asserted-by":"crossref","first-page":"14914","DOI":"10.1038\/s41598-019-50612-3","article-title":"Characterization and prediction of acute and sustained response to psychedelic psilocybin in a mindfulness group retreat","volume":"9","author":"Smigielski","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.pnpbp.2025.111541_bib488","doi-asserted-by":"crossref","DOI":"10.1177\/20503245221124117","article-title":"An interpretative phenomenological analysis of the use of psilocybin by veterans with symptoms of trauma","volume":"8","author":"Smith","year":"2022","journal-title":"Drug Sci. Policy Law"},{"key":"10.1016\/j.pnpbp.2025.111541_bb0450","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.pnpbp.2025.111541_bb0455","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.pnpbp.2025.111541_bb0460","first-page":"512","article-title":"Expectancy effects in psychedelic trials","volume":"9","author":"Szigeti","year":"2024","journal-title":"Biol. Psychiatry: Cognitive Neurosci. Neuroimag."},{"key":"10.1016\/j.pnpbp.2025.111541_bb0465","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s11920-023-01446-4","article-title":"Psychedelic-assisted therapy in military and veterans healthcare systems: clinical, legal, and implementation considerations","volume":"25","author":"Wolfgang","year":"2023","journal-title":"Curr. Psychiatry Rep."},{"key":"10.1016\/j.pnpbp.2025.111541_bb0470","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1007\/s43440-023-00539-4","article-title":"Cardiovascular safety of psychedelic medicine: current status and future directions","volume":"75","author":"Ws\u00f3\u0142","year":"2023","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.pnpbp.2025.111541_bb0475","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2024.115886","article-title":"Efficacy and safety of psychedelics for the treatment of mental disorders: a systematic review and meta-analysis","volume":"335","author":"Yao","year":"2024","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.pnpbp.2025.111541_bb0480","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.5960","article-title":"Acute adverse effects of therapeutic doses of psilocybin: a systematic review and Meta-analysis","volume":"7","author":"Yerubandi","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.pnpbp.2025.111541_bb0485","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1177\/1740774512465064","article-title":"Development of the Stanford expectations of treatment scale (SETS): a tool for measuring patient outcome expectancy in clinical trials","volume":"9","author":"Younger","year":"2012","journal-title":"Clin. Trials"}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584625002957?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584625002957?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T04:50:38Z","timestamp":1773809438000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584625002957"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":94,"alternative-id":["S0278584625002957"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2025.111541","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adverse event reporting and management in psilocybin therapy clinical trials: A systematic review to guide clinical and research protocol development","name":"articletitle","label":"Article Title"},{"value":"Progress in Neuro-Psychopharmacology and Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pnpbp.2025.111541","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"111541"}}